PRIVATE SECTOR READINESS AND PERFORMANCE FOR MALARIA CASE MANAGEMENT IN UGANDA

ASTMH, 65th Annual Meeting, Atlanta, Nov 2016
Henry Kaula1, Peter Buyungo2, ACTwatch Group*1,2

BACKGROUND
The private sector provides about half of all health services in Uganda. The private sector can therefore be a barrier or facilitator to ensuring that suspected malaria cases receive confirmatory testing, and confirmed cases receive appropriate treatment. National malaria outlet surveys conducted between 2010-2013 documented private sector scale-up in availability of malaria testing and quality-assured artemisinin combination therapy (QA-ACT).

METHODS
A 2015 national malaria outlet survey included a fever case management component to measure private sector testing and treatment for fever patients. A census of public and private outlets with potential to distribute malaria testing and/or treatment was conducted among a representative sample of administrative units. In total, 3,433 private sector outlets (private health facilities, pharmacies and drug stores) were screened for availability of malaria testing and treatment, and an audit was completed for all antimalarials, malaria rapid diagnostic tests and microscopy. Where testing and ACT treatment were available, screening identified patients seeking treatment for uncomplicated illness with fever. Consultation observation and exit interviews were conducted with 1,273 eligible fever patients within 1,086 private sector outlets.

RESULTS

Are private sector outlets equipped to test and appropriate treat malaria? The majority of screened private sector outlets had QA-ACT in stock on the day of the survey (72%), and one-third had malaria rapid diagnostic testing (RDT) or microscopy available (32%). In 1 in 4 private sector outlets had both QA-ACT and testing available, and readiness to test and treat was higher among private facilities (53%) and pharmacies (49%) as compared with drug stores (16%) (Figure 1).

Did patients seeking fever treatment in the private sector receive a malaria blood test? Nearly half of all fever patients received a malaria blood test (44%). Nearly one-third of all patients were present at the outlet but did not receive a test (33%), and 1 in 4 patients were not present (caregiver was seeking treatment on their behalf) and therefore could not be tested. Testing was higher among patients seeking care at private facilities (83%) as compared with drug stores and 7.5% at pharmacies. At pharmacies, nearly half of patients were not present (45%), and one-third of patients were not present at drug stores (36%) (Figure 2).

Did patients who tested positive for malaria receive QA ACT treatment? Among patients who tested positive for malaria (N=266), 83% received antimalarial treatment. 60% received treatment with an ACT: line ACT treatment among patients and private sector outlets. One-third of all patients were present at the outlet but did not receive a test (30%), and 1 in 4 patients were not present (caregiver was seeking treatment on their behalf) and therefore could not be tested. Testing was higher among patients seeking care at private facilities (83%) as compared with drug stores and 7.5% at pharmacies. At pharmacies, nearly half of patients were not present (45%), and one-third of patients were not present at drug stores (36%) (Figure 2).

Did patients who tested negative for malaria receive QA ACT treatment? Among patients who tested negative for malaria (N=753), 51% received antimalarial treatment. 43% received treatment with an ACT: line ACT treatment among patients and private sector outlets. One-third of all patients were present at the outlet but did not receive a test (30%), and 1 in 4 patients were not present (caregiver was seeking treatment on their behalf) and therefore could not be tested. Testing was higher among patients seeking care at private facilities (83%) as compared with drug stores and 7.5% at pharmacies. At pharmacies, nearly half of patients were not present (45%), and one-third of patients were not present at drug stores (36%) (Figure 3).

CONCLUSION
In a nationally representative 2015 outlet survey, 1 in 4 private sector outlets had both confirmatory testing and QA-ACT treatment available. Among outlets with testing and treatment available, study results suggest positive private sector performance with respect to testing all fever patients, particularly in health facilities and drug stores, however testing was very low in pharmacies. Not all patients seeking treatment in the private sector can or will be tested for malaria. This is because some private facilities are not present for the consultation (about 1 in 4, including half of patients presenting at pharmacies). Additionally, some patients sought treatment for their fever before seeking treatment at these private sector facilities, and therefore may not have received a malaria test. Patients who tested positive for malaria usually received antimalarial treatment, however only half received QA-ACT. It is in summary possible that many private providers who stock ACT and malaria testing often use available commodities to appropriately manage patients. However, gaps persist in ensuring all fever patients receive a confirmatory test and QA-ACT. There is need to further promote confirmatory testing and fast-line ACT treatment among patients and private sector providers, as well as discourage the use of non-artemisinin therapies and inappropriate use of injectable artemisinin monotherapies for uncomplicated cases.

* ACTwatch is supported by the Bill and Melinda Gates Foundation, DFID and UNITAID. Poster contents do not necessarily reflect the views of the funders. For more information, please visit www.actwatch.info or contact Megan Littrell at mlittrell@alaria.com.

Figure 1: Availability of malaria testing and quality-assured ACT treatment Among all screened outlets

Figure 2: Percentage of patients who received a malaria blood test, across outlet type Among all patients with completed consultation observation and exit interviews, including patients present and not present during the consultation

Figure 3: Treatments received by patients who tested positive for malaria, across outlet type Among all patients with completed consultation observation and exit interviews

Figure 4: Treatments received by patients who tested negative for malaria, across outlet type Among all patients with completed consultation observation and exit interviews

Figure 5: Treatments received by patients who were not tested for malaria, across outlet type Among all patients with completed consultation observation and exit interviews